Concord Biotech Company Overview and Analysis

Concord Biotech is a leading biotechnology company that has made significant strides in the industry. Founded in 1992 by Dr. Ashok Kumar, the company has a rich history of innovation and growth.

Concord Biotech's journey began with a focus on developing high-quality biotechnology products. The company's early success was driven by its commitment to research and development, which enabled it to establish a strong presence in the market.

With a strong foundation in place, Concord Biotech expanded its scope to include a wide range of products and services. Today, the company is a global player in the biotechnology industry, with a diverse portfolio of offerings that cater to various customer needs.

For more insights, see: Holley Performance Products

Concord Biotech is a leading biopharmaceutical company with a strong presence in India. It was founded in 1992.

The company is headquartered in Bengaluru, Karnataka, India. Its research and development facility is located in the same city.

Concord Biotech has a diverse portfolio of products, including vaccines, biologics, and pharmaceuticals. Its products cater to various therapeutic areas, including infectious diseases and cancer.

The company has a strong focus on research and development, with a dedicated team working on new product development.

Worth a look: Housing Development Finance Corporation Stock Price

Concord Biotech has a strong financial foundation, with a revenue of $1.1 billion in 2020.

The company's revenue growth can be attributed to its diversified product portfolio, which includes a range of biotechnology products and services.

Concord Biotech's net income was $150 million in 2020, a significant increase from $100 million in 2019.

Curious to learn more? Check out: Persistent Systems Revenue

Institutional Holdings Trend is an important factor to consider when analyzing a company's financials. Retail holding in the company has almost stayed constant in the last 3 months.

Investors often look at institutional holdings to gauge market sentiment and potential future price movements. In the last 3 months, foreign institutional holding of the company has decreased by 1.07%.

Financials are a crucial aspect of any business or personal financial plan.

In the United States, the average household debt is around $144,000, according to a recent study.

Managing debt is key to financial stability. By paying off high-interest debt and creating a budget, individuals can take control of their finances.

The 50/30/20 rule is a simple and effective way to allocate income: 50% for necessities, 30% for discretionary spending, and 20% for saving and debt repayment.

A unique perspective: Motilal Oswal Financial Services

The company's promoter holding has remained relatively stable over the last 6 months. This suggests a consistent level of commitment from the company's key stakeholders.

In fact, the promoter holding has almost stayed constant in this time period. This stability is a positive sign for investors.

Pledged promoter holdings are insignificant, which means that the promoters are not using their shares as collateral for loans. This suggests that they have sufficient liquidity to support the company's operations.

Concord Biotech has received several regulatory updates and certifications, demonstrating its commitment to maintaining high standards in its operations.

The company has obtained a certificate under Regulation 74(5) of the SEBI(DP) regulations, 2018 for the quarter ended 30.09.2025.

Concord Biotech has also successfully completed various inspections, including the USFDA inspection at its API facility in Dholka, the NAFDAC inspection at its Oral Solid Dosage Unit-2 facility, and the EU GMP inspection at its API facility in Limbassi.

On a similar theme: Concord New Energy

Here is a list of the certifications and inspections Concord Biotech has received:

Concord Biotech has successfully completed a NAFDAC inspection at their Oral Solid Dosage Unit-2 facility in Valthera.

This inspection is a significant milestone for the company, demonstrating their commitment to quality and regulatory compliance.

The inspection was conducted at the facility located in Valthera, and the outcome is a testament to Concord Biotech's rigorous standards and processes.

Concord Biotech has a history of successfully completing regulatory inspections, and this achievement is a continuation of that trend.

The company's dedication to quality and compliance is evident in their ability to pass inspections with flying colors.

Expand your knowledge: Quality Chemical Industries Limited

Concord Biotech has received an Establishment Inspection Report (EIR) for its API facility at Dholka.

This is a significant development, as it indicates that the USFDA has completed its inspection of the facility.

The EIR is a critical document that outlines the findings and observations of the USFDA during the inspection.

It's worth noting that Concord Biotech is a leading player in the Indian pharmaceutical industry, with a strong presence in the domestic and international markets.

The company's API facility at Dholka is a key production site, and the EIR is likely to have a significant impact on the company's operations and future plans.

Here is a list of some of the key stock prices mentioned in the article section:

Our company has been actively engaging with regulatory bodies to ensure compliance with the latest updates. We've been working closely with the FDA to meet the new guidelines for medical device manufacturers.

The new guidelines require manufacturers to submit detailed reports on product testing and clinical trials. This will help ensure the safety and efficacy of medical devices.

We've also been updating our internal processes to reflect the changes in regulations. This includes retraining our quality control team on the new requirements for documentation and record-keeping.

Related reading: New London Ship and Engine Company

The updated regulations also introduce new labeling requirements for medical devices. Manufacturers will need to include clear instructions for use and warnings for potential risks.

Our company is committed to transparency and has been open about the changes we're making to comply with the new regulations. We believe this will help build trust with our customers and stakeholders.

Check this out: New England Shipbuilding Corporation

Concord Biotech Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 08/08/2025 to consider and approve financial results.

The company has made an investment of USD 1500 in Stellon Biotech Inc. through its wholly-owned subsidiary company, Concord Lifegen Limited.

Investor presentations are made pursuant to Regulation 30 of SEBI (LODR) 2015, which provides detailed information on financial results.

Concord Biotech Ltd has announced the incorporation of Concord Lifegen Limited, a wholly-owned subsidiary company, and the closure of the trading window.

The company has also published its BRSR for FY 2024-2025, which includes detailed information on business responsibility and sustainability reporting.

These announcements are made under Regulation 30 of SEBI (LODR) 2015, which requires companies to disclose certain information to the stock exchange.

Concord Biotech Ltd has scheduled analyst/institutional investor meetings on 09th June, 2025 at 10:00 AM to discuss its financial results.

Recommended read: Biotech Investor Relations

Compliances Certificate under SEBI (DP) Regulations 2018 is a crucial document for companies to maintain compliance.

Concord Biotech has recently enclosed a certificate under Regulation 74(5) of the SEBI (DP) regulations, 2018 for the quarter ended 30.09.2025.

The certificate is a requirement under SEBI (DP) regulations, 2018, specifically under Regulation 74(5).

This regulation is designed to ensure that companies maintain accurate and up-to-date records of their compliance.

The certificate is a formal document that confirms Concord Biotech's compliance with the relevant regulations for the specified quarter.

Companies like Concord Biotech must adhere to these regulations to maintain a good standing with the regulatory bodies.

The SEBI (DP) regulations, 2018, are a set of guidelines that govern the activities of companies in the securities market.

Concord Biotech's compliance with these regulations is a testament to their commitment to maintaining high standards of corporate governance.

Concord Biotech's share price is ranked 417 with a market cap of ₹15,926 cr. The stock has a PE Ratio of 42.85 and a PB Ratio of 8.79.

The company's past performance shows moderate financial growth, but it has been a low performer in recent times. Concord Biotech's stock is also considered overvalued compared to the market average.

Here's a comparison of Concord Biotech's stock with its peers:

Shareholding is a crucial aspect of a company's financial health, and it's essential to understand who's behind the scenes. The shareholding pattern of a company can give us valuable insights into its ownership structure.

Promoters hold a significant stake in the company, with 44.08% of shares held by them as of Mar 2025. This percentage has remained consistent across different quarters.

The number of shareholders has been steadily decreasing since Mar 2024, with 83,296 shareholders in Mar 2024, 81,219 in Mar 2025, and 82,650 in Sep 2025.

Foreign Institutional Investors (FIIs) have been increasing their stake in the company, with a 2.86% increase from 6.49% in Mar 2024 to 9.35% in Mar 2025.

Domestic Institutional Investors (DIIs) have also been increasing their stake, with a 0.75% increase from 8.41% in Mar 2024 to 9.16% in Mar 2025.

Here's a summary of the shareholding pattern as of Mar 2025:

The decrease in the number of shareholders and the increase in FIIs and DIIs suggest that institutional investors are playing a significant role in the company's shareholding pattern.

The share price of CONCORDBIO is ₹44.73, which is a relatively moderate price-to-book ratio of 44.73. This is a significant factor to consider when evaluating the stock's value.

The market capitalization of CONCORDBIO is ₹15,926 crore, ranking the stock 417th in the market. This provides a sense of the stock's relative size and position in the market.

The dividend yield of CONCORDBIO is 0.70%, which is a relatively low yield compared to other stocks. This may be a consideration for investors looking for a steady income stream.

Here's a snapshot of CONCORDBIO's key financial metrics:

Let's take a closer look at the performance and comparison of Concord Biotech Ltd and its peers. Concord Biotech Ltd has a PE Ratio of 42.85, which is higher than Sun Pharmaceutical Industries Ltd's PE Ratio of 37.11.

The PB Ratio of Concord Biotech Ltd is 8.79, while Sun Pharmaceutical Industries Ltd has a PB Ratio of 5.60. This indicates that Concord Biotech Ltd is trading at a premium compared to its peer.

Concord Biotech Ltd has a Dividend Yield of 0.70%, which is lower than Sun Pharmaceutical Industries Ltd's Dividend Yield of 0.95%.

Here's a comparison of the stocks' technical metrics:

Concord Biotech Ltd has a Volatility of 45.56%, which is higher than Sun Pharmaceutical Industries Ltd's Volatility of 21.29%. This suggests that Concord Biotech Ltd's stock price is more volatile than its peer.

Concord Biotech Ltd has an RSI - 14D of 29.71, which indicates that its stock price is oversold.

Concord Biotech's Investor Relations team is dedicated to keeping shareholders informed about the company's performance and future prospects. They can be reached through various channels, including email and phone.

The company's investor relations team is led by a seasoned professional with over a decade of experience in the biotech industry. This expertise helps ensure that Concord Biotech's financial information is presented in a clear and transparent manner.

Concord Biotech's investor relations team regularly updates its website with the latest financial reports, including quarterly earnings statements and annual reports. These reports provide a comprehensive overview of the company's financial performance and help investors make informed decisions.

A fresh viewpoint: Jio Financial Services

As an investor, it's essential to know which mutual funds are holding your stocks. Let's take Concord Biotech Ltd as an example.

The HSBC Small Cap Fund - Growth - Direct Plan holds a 0.8835% market-cap of Concord Biotech Ltd.

This fund has a portfolio weight of 0.88% in Concord Biotech Ltd, which is a significant investment.

However, the fund's holding in Concord Biotech Ltd has decreased by 0.05% over the last 3 months.

Here are the top 3 mutual funds holding Concord Biotech Ltd, along with their 3-month holding change:

As you can see, SBI Healthcare Opportunities Fund - Growth - Direct Plan has increased its holding in Concord Biotech Ltd by 0.63% over the last 3 months, making it a fund worth considering.

Broaden your view: Biotech Fund Flanders

Bio mutual funds are a type of investment that focuses on companies with a strong biological or life sciences background.

These funds often invest in companies that develop new medical treatments, technologies, and products.

A key benefit of bio mutual funds is their potential for high growth, as companies in this sector can experience rapid expansion.

However, bio mutual funds can be riskier than other types of investments due to the high stakes involved in medical research and development.

Investors should carefully consider their risk tolerance and financial goals before investing in bio mutual funds.

Some bio mutual funds focus on specific areas, such as biotechnology, pharmaceuticals, or medical devices.

On a similar theme: Biotech Venture Capital Funds

Concord Biotech has been quite active in recent times. They approved a dividend of ₹1 and re-appointed a director, as per their shareholder meeting.

Their standalone June 2025 net sales were at ₹203.99 crore, which is a 5.47% decrease from the previous year. Their stock was also featured in a list of stocks to watch on July 28, 2025, along with other notable companies.

Here are some key corporate actions taken by Concord Biotech:

The trading window for Concord Biotech Ltd's directors and employees was likely closed at some point before August 8, 2025, as they were scheduled to consider and approve the financial results for the first quarter ended on June 30, 2025.

This is a common practice to prevent insider trading and maintain a fair market.

The board meeting was scheduled on August 8, 2025, which indicates that the trading window was closed at least a few days prior to this date.

This allows directors and employees to avoid any potential conflicts of interest and ensures that their personal financial decisions are not influenced by confidential information.

Concord Biotech Ltd informed the BSE about the meeting, which suggests that the trading window was closed in accordance with regulatory requirements.

For another approach, see: State Trading Corporation

Corp. Actions are an essential part of a company's operations, and Concord Biotech is no exception. They provide valuable insights into a company's performance and future prospects.

Concord Biotech has successfully completed an EU GMP inspection, as reported on July 18, 2025. This is a significant achievement for the company.

The company's shareholder meeting was held on September 9, 2025, through video conferencing, as per Regulation 30 of the SEBI (LODR) Regulation, 2015. The meeting was attended by investors and analysts who discussed the company's financial results.

Concord Biotech has also announced its 40th Annual General Meeting, which was scheduled to take place on September 9, 2025. The meeting was held through OAVM (other audio-visual means) and was well-attended by shareholders.

Here's a summary of the company's recent corporate actions:

These corporate actions demonstrate Concord Biotech's commitment to transparency and shareholder engagement. By staying informed about these events, investors can make more informed decisions about their investments.

In corporate actions, a significant event is the acquisition of a company. This can happen when a parent company invests in a subsidiary, making it a wholly owned entity. Concord Biotech Limited made such an investment, incorporating Concord Lifegen Limited as its subsidiary.

The investment amount was substantial, with Concord Biotech Limited investing USD 1500 in Stellon Biotech Inc. This investment likely had a significant impact on Concord Lifegen Limited's operations and financials.

As a result of the acquisition, the trading window for Concord Biotech Limited's shares was closed. This means that the company's employees, directors, and other related parties were prohibited from buying or selling the company's shares during this period.

Consider reading: Cholamandalam Investment and Finance Company

Concord Biotech shareholders have approved a significant dividend of ₹91. This is a notable development for the company and its investors.

The dividend approval was announced recently, and it's a positive sign for the company's financial health. Concord Biotech's standalone June 2025 net sales were at Rs 203.99 crore, which is a 5.47% decrease from the previous year.

Discover more: Vedanta Limited Dividend

Shareholders also re-appointed a director, indicating confidence in the company's leadership. This is a crucial aspect of any company's success.

Concord Biotech has had its share of challenges, including a decline in net sales. However, the company has also achieved notable milestones, such as the successful completion of an EU GMP inspection in July 2025.

Here are some key dates related to the dividend announcement:

These dates are crucial for investors to note, as they will be able to receive the dividend based on the company's records.

CONCORDBIO Forecasts predict a certain path for the company's future. All values in ₹ Thousand cr.

CONCORDBIO has made some significant forecasts, including several key indicators that will shape the company's trajectory.

Analyst Forecasts reveal valuable insights into the market. CONCORDBIO Forecasts are available, providing a comprehensive outlook.

The forecasts are presented in Indian Rupees, specifically in thousands of rupees (₹ Thousand cr.). This makes it easier to understand and analyze the data.

The forecasts are likely to be of interest to investors and market enthusiasts, offering a glimpse into the future of the market.

Concord Biotech has faced revenue challenges, reporting a 5% decline in the first quarter of FY26 primarily due to customer procurement variability and initial costs from a new injectable facility.

The company maintained stable margins and emphasized a robust product pipeline, particularly in the CDMO sector, which is expected to drive future growth.

Concord Biotech has achieved significant regulatory milestones, including receiving US FDA approvals for teriflunomide tablets.

The company has strengthened its presence in the US market through the incorporation of Stellon.

Net income has grown at a yearly rate of 17.06% over the last 5 years, which is lower than the industry average of 20.01%.

Here's a summary of Concord Biotech's performance:

The stock is considered underpriced and not in the overbought zone, according to the CONCORDBIO Stock Scorecard.

Concord Biotech's financials growth has been moderate for a few years, but the company is showing good signs of profitability and efficiency.

The company's stock scorecard suggests that it hasn't fared well amongst the low performers and seems to be overvalued compared to the market average.

The community sentiment is a powerful tool for gauging market direction.

100% of the community is urging investors to BUY, with no one recommending to SELL or HOLD.

Our exclusive webinars and research provide actionable insights that can help you make informed investment decisions.

A key feature of our community is the sharpest opinions, which can be a game-changer for those looking to stay ahead of the market.